88 related articles for article (PubMed ID: 20636794)
1. ERG rearrangement in small cell prostatic and lung cancer.
Scheble VJ; Braun M; Wilbertz T; Stiedl AC; Petersen K; Schilling D; Reischl M; Seitz G; Fend F; Kristiansen G; Perner S
Histopathology; 2010 Jun; 56(7):937-43. PubMed ID: 20636794
[TBL] [Abstract][Full Text] [Related]
2. ERG gene rearrangements are common in prostatic small cell carcinomas.
Lotan TL; Gupta NS; Wang W; Toubaji A; Haffner MC; Chaux A; Hicks JL; Meeker AK; Bieberich CJ; De Marzo AM; Epstein JI; Netto GJ
Mod Pathol; 2011 Jun; 24(6):820-8. PubMed ID: 21336263
[TBL] [Abstract][Full Text] [Related]
3. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
4. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
5. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
[TBL] [Abstract][Full Text] [Related]
7. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
[TBL] [Abstract][Full Text] [Related]
9. ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.
Scheble VJ; Scharf G; Braun M; Ruiz C; Stürm S; Petersen K; Beschorner R; Bachmann A; Zellweger T; Fend F; Kristiansen G; Bubendorf L; Wernert N; Adler D; Perner S
Virchows Arch; 2012 Aug; 461(2):157-62. PubMed ID: 22767266
[TBL] [Abstract][Full Text] [Related]
10. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
11. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
Falzarano SM; Zhou M; Carver P; Tsuzuki T; Simmerman K; He H; Magi-Galluzzi C
Virchows Arch; 2011 Oct; 459(4):441-7. PubMed ID: 21773753
[TBL] [Abstract][Full Text] [Related]
12. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract][Full Text] [Related]
13. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
Svensson MA; Perner S; Ohlson AL; Day JR; Groskopf J; Kirsten R; Sollie T; Helenius G; Andersson SO; Demichelis F; Andrén O; Rubin MA
Appl Immunohistochem Mol Morphol; 2014; 22(2):136-41. PubMed ID: 24517914
[TBL] [Abstract][Full Text] [Related]
15. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.
Williamson SR; Zhang S; Yao JL; Huang J; Lopez-Beltran A; Shen S; Osunkoya AO; MacLennan GT; Montironi R; Cheng L
Mod Pathol; 2011 Aug; 24(8):1120-7. PubMed ID: 21499238
[TBL] [Abstract][Full Text] [Related]
16. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
[TBL] [Abstract][Full Text] [Related]
18. High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S; Luebke AM; Kluth M; Bokemeyer C; Jänicke F; Izbicki J; Schlomm T; Sauter G; Wilczak W
Histopathology; 2012 Sep; 61(3):445-53. PubMed ID: 22463702
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
20. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
Braun M; Goltz D; Adler D; Vogel W; Böhm D; Scheble V; Sotlar K; Fend F; Tan SH; Dobi A; Kristiansen G; Wernert N; Perner S
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):165-9. PubMed ID: 22231490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
